罗氏公司的药物阿斯泰戈利马布在减少COPD严重恶化症的可能性高达15.4%. Roche's drug astegolimab shows promise in reducing severe COPD exacerbations by up to 15.4%.

Roche在两次治疗严重抗逆转录病毒药物的Astegolimab试验中公布了结果。 Roche has released results from two trials of the drug astegolimab for treating severe COPD. 第二阶段b试验显示,在一年中,恶化率在统计上显著下降了15.4%,而第三阶段试验没有达到其主要目标,但减少了14.5%。 The phase IIb trial showed a statistically significant 15.4% reduction in exacerbation rates over a year, while the phase III trial did not meet its primary goal but showed a 14.5% reduction. 该药物的安全情况与以前的数据是一致的。 The drug's safety profile was consistent with previous data. 将在未来的医疗会议上提出详细的调查结果。 Detailed findings will be presented at a future medical conference.